Tolazamide (BioDeep_00000014993)

代谢物信息卡片

Tolazamide

化学式: C14H21N3O3S (311.1304)
中文名称: 妥拉磺脲
谱图信息: 最多检出来源 Homo sapiens(blood) 10%

分子结构信息

SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
InChI: InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)

描述信息

A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent
D007004 - Hypoglycemic Agents
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4274; ORIGINAL_PRECURSOR_SCAN_NO 4272
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4225; ORIGINAL_PRECURSOR_SCAN_NO 4223
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4245; ORIGINAL_PRECURSOR_SCAN_NO 4243
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4316; ORIGINAL_PRECURSOR_SCAN_NO 4314
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4224; ORIGINAL_PRECURSOR_SCAN_NO 4220
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8447; ORIGINAL_PRECURSOR_SCAN_NO 8445
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8470; ORIGINAL_PRECURSOR_SCAN_NO 8469
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8494; ORIGINAL_PRECURSOR_SCAN_NO 8491
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8497; ORIGINAL_PRECURSOR_SCAN_NO 8496
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8468; ORIGINAL_PRECURSOR_SCAN_NO 8463
CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8506; ORIGINAL_PRECURSOR_SCAN_NO 8504

同义名列表

2 个代谢物同义名

Tolazamide; Tolazamide

数据库引用编号

20 个数据库交叉引用编号

ChEBI: CHEBI:9613
KEGG: C71499
KEGGdrug: D00379
PubChem: 5503
Metlin: METLIN43354
DrugBank: DB00839
ChEMBL: CHEMBL817
MeSH: Tolazamide
CAS: 1156-19-0
MoNA: LU027256
MoNA: LU027255
MoNA: LU027254
MoNA: LU027252
MoNA: LU027251
MoNA: LU027206
MoNA: LU027205
MoNA: LU027204
MoNA: LU027203
MoNA: LU027202
MoNA: LU027201

分类词条

苯环型化合物

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位		关联基因列表

文献列表

Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
Pingyang Tao, Zhao Li, Ashley G Woolfork, David S Hage. Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography. Journal of pharmaceutical and biomedical analysis. 2019 Mar; 166(?):273-280. doi: 10.1016/j.jpba.2019.01.025. [PMID: 30682693]
Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
Holger Rehmann. Epac2: a sulfonylurea receptor?. Biochemical Society transactions. 2012 Feb; 40(1):6-10. doi: 10.1042/bst20110640. [PMID: 22260657]
Man-Wo Tsang. The management of type 2 diabetic patients with hypoglycaemic agents. ISRN endocrinology. 2012; 2012(?):478120. doi: 10.5402/2012/478120. [PMID: 22645689]
Elbert S Huang, Jennifer Y Liu, Howard H Moffet, Priya M John, Andrew J Karter. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes care. 2011 Jun; 34(6):1329-36. doi: 10.2337/dc10-2377. [PMID: 21505211]
Gisela I Robles, Devada Singh-Franco. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug design, development and therapy. 2009 Sep; 3(?):219-40. doi: 10.2147/dddt.s3321. [PMID: 19920937]
Ana Jovanovic, Jean Gerrard, Roy Taylor. The second-meal phenomenon in type 2 diabetes. Diabetes care. 2009 Jul; 32(7):1199-201. doi: 10.2337/dc08-2196. [PMID: 19366973]
Loretta Aureli, Gabriele Cruciani, Maria Candida Cesta, Roberto Anacardio, Lucio De Simone, Alessio Moriconi. Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. Journal of medicinal chemistry. 2005 Apr; 48(7):2469-79. doi: 10.1021/jm049227l. [PMID: 15801837]
Jason I Biederman, Edgard Vera, Rohit Rankhaniya, Clare Hassett, Giovanna Giannico, Jerry Yee, Pedro Cortes. Effects of sulfonylureas, alpha-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes. Kidney international. 2005 Feb; 67(2):554-65. doi: 10.1111/j.1523-1755.2005.67112.x. [PMID: 15673303]
Mark C Granberry, Vivian A Fonseca. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2005; 5(3):201-9. doi: 10.2165/00129784-200505030-00006. [PMID: 15901207]
Emmie N M Ho, Kenneth C H Yiu, Terence S M Wan, Brian D Stewart, Keith L Watkins. Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Nov; 811(1):65-73. doi: 10.1016/j.jchromb.2004.03.070. [PMID: 15458724]
Mary U Kabadi, Udaya M Kabadi. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. The Annals of pharmacotherapy. 2003 Nov; 37(11):1572-6. doi: 10.1345/aph.1c492. [PMID: 14565810]
Hans H Maurer, Carsten Kratzsch, Thomas Kraemer, Frank T Peters, Armin A Weber. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Jun; 773(1):63-73. doi: 10.1016/s1570-0232(01)00618-3. [PMID: 12015271]
G Colmenarejo, A Alvarez-Pedraglio, J L Lavandera. Cheminformatic models to predict binding affinities to human serum albumin. Journal of medicinal chemistry. 2001 Dec; 44(25):4370-8. doi: 10.1021/jm010960b. [PMID: 11728183]
P Cortes, B L Riser, K Asano, A Rodríguez-Barbero, R G Narins, J Yee. Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Kidney international. 1998 Dec; 54(6):1985-98. doi: 10.1046/j.1523-1755.1998.00207.x. [PMID: 9853263]
J A Pugh, M L Wagner, J Sawyer, G Ramirez, M Tuley, S J Friedberg. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes care. 1992 Aug; 15(8):953-9. doi: 10.2337/diacare.15.8.953. [PMID: 1387073]
R Sanders, B Faro, P Stoler, G J Mick, K L McCormick. Adjunctive use of tolazamide in newly-diagnosed diabetic children. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1990 Nov; 22(11):576-80. doi: 10.1055/s-2007-1004977. [PMID: 2272604]
U M Kabadi, M R Birkenholz. Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. Archives of internal medicine. 1988 Aug; 148(8):1745-9. doi: NULL. [PMID: 3041937]
J D Lev, A Zeidler, D Kumar. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide. Diabetes care. 1987 Nov; 10(6):679-82. doi: 10.2337/diacare.10.6.679. [PMID: 3123183]
A E Kitabchi, A G Soria, A Radparvar, V Lawson-Grant. Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. The American journal of the medical sciences. 1987 Jul; 294(1):10-4. doi: 10.1097/00000441-198707000-00002. [PMID: 3605188]
J H Karam, N Sanz, E Salamon, M S Nolte. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes. 1986 Dec; 35(12):1314-20. doi: 10.2337/diab.35.12.1314. [PMID: 3533680]
C A Skillman, H P Fletcher. 2-Deoxyglucose tissue levels and insulin levels following tolazamide dosing in normal and obese mice. Experimental and clinical endocrinology. 1986 Aug; 87(3):288-98. doi: 10.1055/s-0029-1210557. [PMID: 3536534]
B L Maloff, B K Boyd. Physiologic and cellular insulin action in a glucose-intolerant model of type 2 (non-insulin-dependent) diabetes in rats. Diabetologia. 1986 May; 29(5):295-300. doi: 10.1007/bf00452066. [PMID: 3522328]
A Reich, C Abraira, R Brunken, I Soneru. Potentiation of glucose-stimulated insulin release by tolazamide and paradoxical absence of glucose facilitation (Staub effect) in non-insulin-dependent diabetes. Metabolism: clinical and experimental. 1986 Apr; 35(4):367-70. doi: 10.1016/0026-0495(86)90157-5. [PMID: 3515119]
M P Longnecker, V D Elsenhans, S M Leiman, O E Owen, G Boden. Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. Archives of internal medicine. 1986 Apr; 146(4):673-6. doi: NULL. [PMID: 3516096]
C Bogardus, M R Taskinen, J Zawadzki, S Lillioja, D Mott, B V Howard. Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. Diabetes. 1986 Jan; 35(1):1-5. doi: 10.2337/diab.35.1.1. [PMID: 3940908]
F B Davis, A Van Son, P J Davis, L Edwards. Urinary diluting capacity in elderly diabetic subjects. Experimental gerontology. 1986; 21(4-5):407-12. doi: 10.1016/0531-5565(86)90045-8. [PMID: 3817044]
B V Howard, P Xiaoren, I Harper, J E Foley, M C Cheung, M R Taskinen. Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. The American journal of medicine. 1985 Sep; 79(3B):78-85. doi: 10.1016/s0002-9343(85)80012-7. [PMID: 4050825]
U M Kabadi. Adjuvant therapy with tolazamide and insulin improves metabolic control in type I diabetes mellitus. Diabetes care. 1985 Sep; 8(5):440-6. doi: 10.2337/diacare.8.5.440. [PMID: 3902422]
B D Prendergast. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clinical pharmacy. 1984 Sep; 3(5):473-85. doi: . [PMID: 6435940]
L J Mandarino, J E Gerich. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes care. 1984 May; 7 Suppl 1(?):89-99. doi: NULL. [PMID: 6376034]
M L McCaleb, B L Maloff, S M Nowak, D H Lockwood. Sulfonylurea effects on target tissues for insulin. Diabetes care. 1984 May; 7 Suppl 1(?):42-6. doi: NULL. [PMID: 6376028]
J M Amatruda, A I Salhanick, C L Chang. Hepatic insulin resistance in non-insulin-dependent diabetes mellitus and the effects of a sulfonylurea in potentiating insulin action. Diabetes care. 1984 May; 7 Suppl 1(?):47-53. doi: NULL. [PMID: 6376029]
R W Sloan, R M Kreider, J R Luderer. The effect of chlorpropamide hyponatremia on mental status in a nursing home population. The Journal of family practice. 1983 May; 16(5):937-42. doi: NULL. [PMID: 6842150]
S M Nowak, M L McCaleb, D H Lockwood. Extrapancreatic action of sulfonylureas: hypoglycemic effects are not dependent on altered insulin binding or inhibition of transglutaminase. Metabolism: clinical and experimental. 1983 Apr; 32(4):398-402. doi: 10.1016/0026-0495(83)90050-1. [PMID: 6137754]
A I Salhanick, P Konowitz, J M Amatruda. Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats. Diabetes. 1983 Mar; 32(3):206-12. doi: 10.2337/diab.32.3.206. [PMID: 6337899]
P G Welling, R B Patel, U R Patel, W R Gillespie, W A Craig, K S Albert. Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. Journal of pharmaceutical sciences. 1982 Nov; 71(11):1259-63. doi: 10.1002/jps.2600711119. [PMID: 7175719]
F B Davis, D M Boh, P J Davis, A R van Son, K M Mylotte, L Edwards, M Zielezny, C Sczupak. Factors moderating the effect of oral sulfonylureas on free water clearance. Journal of clinical pharmacology. 1982 Feb; 22(2-3):97-101. doi: 10.1002/j.1552-4604.1982.tb02655.x. [PMID: 7068939]
J S Coxe, T M O'Dorisio, S Cataland, S E Crockett. Gastric inhibitory polypeptide hypersecretion in diabetes mellitus: effect of sulfonylurea treatment. The Journal of clinical endocrinology and metabolism. 1981 May; 52(5):1002-5. doi: 10.1210/jcem-52-5-1002. [PMID: 7014585]
T A Schultz, S B Lewis, J L Davis, C R Rost, M M Bliziotes. Effect of sulfonylurea therapy and plasma glucose levels on hemoglobin A1c in type II diabetes mellitus. The American journal of medicine. 1981 Feb; 70(2):373-8. doi: 10.1016/0002-9343(81)90774-9. [PMID: 7468619]
T G Skillman, J M Feldman. The pharmacology of sulfonylureas. The American journal of medicine. 1981 Feb; 70(2):361-72. doi: 10.1016/0002-9343(81)90773-7. [PMID: 6781341]
G Boden, R W Master, S S Gordon, C R Shuman, O E Owen. Monitoring metabolic control in diabetic outpatients with glycosylated hemoglobin. Annals of internal medicine. 1980 Mar; 92(3):357-60. doi: 10.7326/0003-4819-92-3-357. [PMID: 7356230]
H A Milman, J C Peckham, J M Ward, R E Tarone. Reduction of the severity of nephropathy in aging Fischer 344 rats treated with analogs of arylsulfonyluria. Toxicology and applied pharmacology. 1979 Jul; 49(3):425-30. doi: 10.1016/0041-008x(79)90442-3. [PMID: 473209]
R C Thomas, D J Duchamp, R W Judy, G J Ikeda. Metabolic fate of tolazamide in man and in the rat. Journal of medicinal chemistry. 1978 Aug; 21(8):725-32. doi: 10.1021/jm00206a002. [PMID: 690998]
R Schmeltz, H J Wendorff, J B Field. Effect of control of blood glucose on plasma insulin responses to various stimuli in secondary failures to oral hypoglycemic agents and in newly diagnosed, maturity onset, ketosis-resistant diabetics. The Journal of clinical endocrinology and metabolism. 1978 Apr; 46(4):519-27. doi: 10.1210/jcem-46-4-519. [PMID: 755038]
T A LoIudice, J A Lang. Tolazamide-induced hepatic dysfunction. The American journal of gastroenterology. 1978 Jan; 69(1):81-3. doi: NULL. [PMID: 645691]
D J Kudzma, S J Friedberg. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate. Diabetes. 1977 Apr; 26(4):291-5. doi: 10.2337/diab.26.4.291. [PMID: 321288]
E Tsalikian, T W Dunphy, N V Bohannon, M Lorenzi, J E Gerich, P H Forsham, J P Kane, J H Karam. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Diabetes. 1977 Apr; 26(4):314-21. doi: 10.2337/diab.26.4.314. [PMID: 849812]
S W Shen, R Bressler. Clinical pharmacology of oral antidiabetic agents (first of two parts). The New England journal of medicine. 1977 Mar; 296(9):493-7. doi: 10.1056/nejm197703032960906. [PMID: 319363]
B M Sheikholislam, J J Irias, G H Lowrey, H J Lin. Carbohydrate metabolism and capillary basement-membrane thickness in children. II. Longitudinal studies. Diabetes. 1976 Aug; 25(8):661-6. doi: 10.2337/diab.25.8.661. [PMID: 955297]
R Coulson, A M Moses. Effect of chlorpropamide on renal response to parathyroid hormone in normal subjects and in patients with hypoparathyroidism and pseudohypoparathyroidism. The Journal of pharmacology and experimental therapeutics. 1975 Sep; 194(3):603-13. doi: NULL. [PMID: 169346]
M J Crooks, K F Brown. The binding of sulphonylureas to serum albumin. The Journal of pharmacy and pharmacology. 1974 May; 26(5):304-11. doi: 10.1111/j.2042-7158.1974.tb09280.x. [PMID: 4153105]
S Tuma, P Syzlman, O S Better. Augmented urinary dilution following administration of tolinase in man. Nephron. 1974; 13(2):144-51. doi: NULL. [PMID: 4850701]
H de Baere, P Decraene, I de Leeuw, P Lemmens, H Verhaegen. [Hypoglycemia caused by oral antidiabetic agents]. Nederlands tijdschrift voor geneeskunde. 1973 Jul; 117(27):1021-4. doi: NULL. [PMID: 4206176]
A M Moses, J Howanitz, M Miller. Diuretic action of three sulfonylurea drugs. Annals of internal medicine. 1973 Apr; 78(4):541-4. doi: 10.7326/0003-4819-78-4-541. [PMID: 4632790]
G D Molnar, W F Taylor, A L Langworthy. Plasma immunoreactive insulin patterns in insulin-treated diabetics. Studies during continuous blood glucose monitoring. Mayo Clinic proceedings. 1972 Oct; 47(10):709-19. doi: NULL. [PMID: 4635563]
J A Wickramasinghe, S R Shaw. GC determination of tolazamide in plasma. Journal of pharmaceutical sciences. 1971 Nov; 60(11):1669-72. doi: 10.1002/jps.2600601117. [PMID: 5133917]
M Garcia, M Miller, A M Moses. Chlorpropamide-induced water retention in patients with diabetes mellitus. Annals of internal medicine. 1971 Oct; 75(4):549-54. doi: 10.7326/0003-4819-75-4-549. [PMID: 5094069]
J R Turtle. Glucose and insulin secretory response patterns following diet and tolazamide therapy in diabetes. British medical journal. 1970 Sep; 3(5723):606-10. doi: 10.1136/bmj.3.5723.606. [PMID: 5470087]
J Gormsen, B Laursen. Studies on pharmacological enhancement of blood fibrinolytic activity. Angiology. 1970 Sep; 21(8):546-51. doi: 10.1177/000331977002100807. [PMID: 4990278]
B Laursen, J Gormsen. Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity. Scandinavian journal of haematology. 1969; 6(6):402-8. doi: NULL. [PMID: 5374117]
J A Rull, M Lennhoff. Prolonged and recurrent tolazamide-induced hypoglycemia. Report of a case. Diabetes. 1967 May; 16(5):352-3. doi: 10.2337/diab.16.5.352. [PMID: 6022563]
J A Moorhouse. A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects. Canadian Medical Association journal. 1967 Mar; 96(9):536-9. doi: NULL. [PMID: 6019354]
E López Amor, O Lozano Castañeda, L Domenque. [Effect of tolazamide on serum cholesterol]. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 1966 Apr; 18(2):229-37. doi: NULL. [PMID: 5973929]
D L SMITH, T J VECCHIO, A A FORIST. METABOLISM OF ANTIDIABETIC SULFONYLUREAS IN MAN. I. BIOLOGICAL HALF-LIVES OF THE P-ACETYLBENZENESULFONYLUREAS, U-18536 AND ACETOHEXAMIDE AND THEIR METABOLITES. Metabolism: clinical and experimental. 1965 Mar; 14(?):229-40. doi: 10.1016/0026-0495(65)90063-6. [PMID: 14261407]
L ROJAS, L COLINABRACHO, L DOMENGE. [CLINICAL EVALUATION OF A NEW HYPOGLYCEMIC AGENT WITH CHOLESTEROLEMIC ACTION (TOLAZAMIDE). PRELIMINARY REPORT]. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 1964 Apr; 16(?):173-82. doi: ". [PMID: 14170236]